Skip to main content
Top
Published in: BMC Complementary Medicine and Therapies 1/2015

Open Access 01-12-2015 | Research article

Identification of anti-inflammatory fractions of Geranium wilfordii using tumor necrosis factor-alpha as a drug target on Herbochip® – an array-based high throughput screening platform

Authors: Min Huang, Pei-Wun Yao, Margaret Dah-Tysr Chang, Sim-Kun Ng, Chien-Hui Yu, Yun-feng Zhang, Meng-Liang Wen, Xiao-yuan Yang, Yiu-Kay Lai

Published in: BMC Complementary Medicine and Therapies | Issue 1/2015

Login to get access

Abstract

Background

Geranium wilfordii is one of the major species used as Herba Geranii (lao-guan-cao) in China, it is commonly used solely or in polyherbal formulations for treatment of joint pain resulted from rheumatoid arthritis (RA) and gout. This herb is used to validate a target-based drug screening platform called Herbochip® and evaluate anti-inflammatory effects of Geranium wilfordii ethanolic extract (GWE) using tumor necrosis factor-alpha (TNF-α) as a drug target together with subsequent in vitro and in vivo assays.

Methods

A microarray-based drug screening platform was constructed by arraying HPLC fractions of herbal extracts onto a surface-activated polystyrene slide (Herbochip®). Using TNF-α as a molecular probe, fractions of 82 selected herbal extracts, including GWE, were then screened to identify plant extracts containing TNF-α-binding agents. Cytotoxicity of GWE and modulatory effects of GWE on TNF-α expression were evaluated by cell-based assays using TNF-α sensitive murine fibrosarcoma L929 cells as an in vitro model.

Results

The in vivo anti-inflammatory effects of GWE were further assessed by animal models including carrageenan-induced hind paw edema in rats and xylene-induced ear edema in mice, in comparison with aspirin. The hybridization data obtained by Herbochip® analysis showed unambiguous signals which confirmed TNF-α binding activity in 46 herbal extracts including GWE. In L929 cells GWE showed significant inhibitory effect on TNF-α expression with negligible cytotoxicity. GWE also significantly inhibited formation of carrageenan-induced hind paw edema and xylene-induced ear edema in animal models, indicating that it indeed possessed anti-inflammatory activity.

Conclusion

We have thus validated effectiveness of the Herbochip® drug screening platform using TNF-α as a molecular target. Subsequent experiments on GWE lead us to conclude that the anti-RA activity of GWE can be attributed to inhibitory effect of GWE on the key inflammatory factor, TNF-α. Our results contribute towards validation of the traditional use of GWE in the treatment of RA and other inflammatory joint disorders.
Literature
1.
go back to reference Medical BC. Pharmacopoeia of Peopleʼs Republic of China, Part 1. 2010. Medical BC. Pharmacopoeia of Peopleʼs Republic of China, Part 1. 2010.
2.
go back to reference Kupeli E, Tatli II, Akdemir ZS, Yesilada E. Estimation of antinociceptive and anti-inflammatory activity on Geranium pratense subsp. finitimum and its phenolic compounds. J Ethnopharmacol. 2007;114(2):234–40.CrossRefPubMed Kupeli E, Tatli II, Akdemir ZS, Yesilada E. Estimation of antinociceptive and anti-inflammatory activity on Geranium pratense subsp. finitimum and its phenolic compounds. J Ethnopharmacol. 2007;114(2):234–40.CrossRefPubMed
3.
go back to reference Li J, Huang H, Feng M, Zhou W, Shi X, Zhou P. In vitro and in vivo anti-hepatitis B virus activities of a plant extract from Geranium carolinianum L. Antiviral Res. 2008;79(2):114–20.CrossRefPubMed Li J, Huang H, Feng M, Zhou W, Shi X, Zhou P. In vitro and in vivo anti-hepatitis B virus activities of a plant extract from Geranium carolinianum L. Antiviral Res. 2008;79(2):114–20.CrossRefPubMed
4.
go back to reference Boissier MC. Cell and cytokine imbalances in rheumatoid synovitis. Joint, Bone, Spine :Rev Rhum. 2011;78(3):230–4.CrossRef Boissier MC. Cell and cytokine imbalances in rheumatoid synovitis. Joint, Bone, Spine :Rev Rhum. 2011;78(3):230–4.CrossRef
5.
go back to reference Boissier MC, Semerano L, Challal S, Saidenberg-Kermanac’h N, Falgarone G. Rheumatoid arthritis: from autoimmunity to synovitis and joint destruction. J Autoimmun. 2012;39(3):222–8.CrossRefPubMed Boissier MC, Semerano L, Challal S, Saidenberg-Kermanac’h N, Falgarone G. Rheumatoid arthritis: from autoimmunity to synovitis and joint destruction. J Autoimmun. 2012;39(3):222–8.CrossRefPubMed
6.
go back to reference Lipsky PE. Rheumatoid arthritis. In: Kasper DL, Braunwald EB, Fauci AS, Hauser SL, Longo DL, Jameson JL, editors. Harrison’s principles of internal medicine. 2005. Lipsky PE. Rheumatoid arthritis. In: Kasper DL, Braunwald EB, Fauci AS, Hauser SL, Longo DL, Jameson JL, editors. Harrison’s principles of internal medicine. 2005.
7.
go back to reference Scott DL, Kingsley GH. Tumor necrosis factor inhibitors for rheumatoid arthritis. N Engl J Med. 2006;355(7):704–12.CrossRefPubMed Scott DL, Kingsley GH. Tumor necrosis factor inhibitors for rheumatoid arthritis. N Engl J Med. 2006;355(7):704–12.CrossRefPubMed
8.
go back to reference Hetland ML, Christensen IJ, Tarp U, Dreyer L, Hansen A, Hansen IT, et al. Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry. Arthritis Rheum. 2010;62(1):22–32.CrossRefPubMed Hetland ML, Christensen IJ, Tarp U, Dreyer L, Hansen A, Hansen IT, et al. Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry. Arthritis Rheum. 2010;62(1):22–32.CrossRefPubMed
9.
go back to reference Rubbert-Roth A. Assessing the safety of biologic agents in patients with rheumatoid arthritis. Rheumatology (Oxford). 2012;51 Suppl 5:v38–47.CrossRef Rubbert-Roth A. Assessing the safety of biologic agents in patients with rheumatoid arthritis. Rheumatology (Oxford). 2012;51 Suppl 5:v38–47.CrossRef
10.
go back to reference Eisenberg DM, Davis RB, Ettner SL, Appel S, Wilkey S, Van Rompay M, et al. Trends in alternative medicine use in the United States, 1990–1997: results of a follow-up national survey. JAMA. 1998;280(18):1569–75.CrossRefPubMed Eisenberg DM, Davis RB, Ettner SL, Appel S, Wilkey S, Van Rompay M, et al. Trends in alternative medicine use in the United States, 1990–1997: results of a follow-up national survey. JAMA. 1998;280(18):1569–75.CrossRefPubMed
11.
go back to reference Kaptchuk TJ, Eisenberg DM. The persuasive appeal of alternative medicine. Ann Intern Med. 1998;129(12):1061–5.CrossRefPubMed Kaptchuk TJ, Eisenberg DM. The persuasive appeal of alternative medicine. Ann Intern Med. 1998;129(12):1061–5.CrossRefPubMed
12.
go back to reference World Health Organization. WHO traditional medicine strategy 2002-2005. Geneva: WHO; 2002. World Health Organization. WHO traditional medicine strategy 2002-2005. Geneva: WHO; 2002.
13.
go back to reference Nicoletti M. Nutraceuticals and botanicals: overview and perspectives. Int J Food Sci Nutr. 2012;63 Suppl 1:2–6.CrossRefPubMed Nicoletti M. Nutraceuticals and botanicals: overview and perspectives. Int J Food Sci Nutr. 2012;63 Suppl 1:2–6.CrossRefPubMed
14.
go back to reference Yue QX, Liu X, Guo DA. Microtubule-binding natural products for cancer therapy. Planta Med. 2010;76(11):1037–43.CrossRefPubMed Yue QX, Liu X, Guo DA. Microtubule-binding natural products for cancer therapy. Planta Med. 2010;76(11):1037–43.CrossRefPubMed
15.
go back to reference Eckstein-Ludwig U, Webb RJ, Van Goethem ID, East JM, Lee AG, Kimura M, et al. Artemisinins target the SERCA of Plasmodium falciparum. Nature. 2003;424(6951):957–61.CrossRefPubMed Eckstein-Ludwig U, Webb RJ, Van Goethem ID, East JM, Lee AG, Kimura M, et al. Artemisinins target the SERCA of Plasmodium falciparum. Nature. 2003;424(6951):957–61.CrossRefPubMed
16.
go back to reference Krishna S, Uhlemann AC, Haynes RK. Artemisinins: mechanisms of action and potential for resistance. Drug Resist Updat. 2004;7(4–5):233–44.CrossRefPubMed Krishna S, Uhlemann AC, Haynes RK. Artemisinins: mechanisms of action and potential for resistance. Drug Resist Updat. 2004;7(4–5):233–44.CrossRefPubMed
17.
go back to reference Chang SCHL, Chen JP, Lee JW. Herbal chip. 2003. Chang SCHL, Chen JP, Lee JW. Herbal chip. 2003.
18.
go back to reference Lee SS, Zhang B, He ML, Chang VS, Kung HF. Screening of active ingredients of herbal medicine for interaction with CYP450 3A4. PTR. 2007;21(11):1096–9.PubMed Lee SS, Zhang B, He ML, Chang VS, Kung HF. Screening of active ingredients of herbal medicine for interaction with CYP450 3A4. PTR. 2007;21(11):1096–9.PubMed
19.
go back to reference Liu B, Zhang B, Min MW, Bian HJ, Chen LF, Liu Q, et al. Induction of apoptosis by Polygonatum odoratum lectin and its molecular mechanisms in murine fibrosarcoma L929 cells. Biochim Biophys Acta. 2009;1790(8):840–4.CrossRefPubMed Liu B, Zhang B, Min MW, Bian HJ, Chen LF, Liu Q, et al. Induction of apoptosis by Polygonatum odoratum lectin and its molecular mechanisms in murine fibrosarcoma L929 cells. Biochim Biophys Acta. 2009;1790(8):840–4.CrossRefPubMed
20.
go back to reference Kiemer AK, Muller C, Vollmar AM. Inhibition of LPS-induced nitric oxide and TNF-alpha production by alpha-lipoic acid in rat Kupffer cells and in RAW 264.7 murine macrophages. Immunol Cell Biol. 2002;80(6):550–7.CrossRefPubMed Kiemer AK, Muller C, Vollmar AM. Inhibition of LPS-induced nitric oxide and TNF-alpha production by alpha-lipoic acid in rat Kupffer cells and in RAW 264.7 murine macrophages. Immunol Cell Biol. 2002;80(6):550–7.CrossRefPubMed
21.
go back to reference Zhu Y, Zhang Z, Zhang M, Mais DE, Wang MW. High-throughput screening for bioactive components from traditional Chinese medicine. Comb Chem High Throughput Screen. 2010;13(10):837–48.CrossRefPubMed Zhu Y, Zhang Z, Zhang M, Mais DE, Wang MW. High-throughput screening for bioactive components from traditional Chinese medicine. Comb Chem High Throughput Screen. 2010;13(10):837–48.CrossRefPubMed
22.
go back to reference Mayr LM, Bojanic D. Novel trends in high-throughput screening. Curr Opin Pharmacol. 2009;9(5):580–8.CrossRefPubMed Mayr LM, Bojanic D. Novel trends in high-throughput screening. Curr Opin Pharmacol. 2009;9(5):580–8.CrossRefPubMed
23.
go back to reference Naoghare PK, Song JM. Chip-based high-throughput screening of herbal medicines. Comb Chem High Throughput Screen. 2010;13(10):923–31.CrossRefPubMed Naoghare PK, Song JM. Chip-based high-throughput screening of herbal medicines. Comb Chem High Throughput Screen. 2010;13(10):923–31.CrossRefPubMed
24.
go back to reference Kiltz U, Heldmann F, Baraliakos X, Braun J. Treatment of ankylosing spondylitis in patients refractory to TNF-inhibition: are there alternatives? Curr Opin Rheumatol. 2012;24(3):252–60.CrossRefPubMed Kiltz U, Heldmann F, Baraliakos X, Braun J. Treatment of ankylosing spondylitis in patients refractory to TNF-inhibition: are there alternatives? Curr Opin Rheumatol. 2012;24(3):252–60.CrossRefPubMed
25.
go back to reference Tanaka Y. Intensive treatment and treatment holiday of TNF-inhibitors in rheumatoid arthritis. Curr Opin Rheumatol. 2012;24(3):319–26.CrossRefPubMed Tanaka Y. Intensive treatment and treatment holiday of TNF-inhibitors in rheumatoid arthritis. Curr Opin Rheumatol. 2012;24(3):319–26.CrossRefPubMed
Metadata
Title
Identification of anti-inflammatory fractions of Geranium wilfordii using tumor necrosis factor-alpha as a drug target on Herbochip® – an array-based high throughput screening platform
Authors
Min Huang
Pei-Wun Yao
Margaret Dah-Tysr Chang
Sim-Kun Ng
Chien-Hui Yu
Yun-feng Zhang
Meng-Liang Wen
Xiao-yuan Yang
Yiu-Kay Lai
Publication date
01-12-2015
Publisher
BioMed Central
Published in
BMC Complementary Medicine and Therapies / Issue 1/2015
Electronic ISSN: 2662-7671
DOI
https://doi.org/10.1186/s12906-015-0665-9

Other articles of this Issue 1/2015

BMC Complementary Medicine and Therapies 1/2015 Go to the issue